Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 15/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | MMP14 | P50281 | 10/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942531 | 1.00 | MMP13 (0.43) | MMP13MMP12MMP14ADAMTS5COMT | |
| SCHEMBL941134 | 0.95 | MMP13 (0.44) | MMP13MMP12MMP14ADAMTS5COMT | |
| SCHEMBL942308 | 0.84 | MMP13 (0.46) | MMP13MMP12MMP14ADAMTS5HTR7 | |
| SCHEMBL941824 | 0.82 | MMP13 (0.41) | MMP13MMP12MMP14ADAMTS5HTR7 | |
| SCHEMBL3550561 | 0.76 | ADAMTS5 (0.40) | MMP13MMP12ADAMTS5HTR7 | |
| SCHEMBL942265 | 0.76 | MMP13 (0.49) | MMP13MMP12MMP14 | |
| SCHEMBL941012 | 0.76 | MMP13 (0.49) | MMP13MMP12MMP14 | |
| SCHEMBL940748 | 0.76 | MMP13 (0.48) | MMP13MMP12MMP14ADAMTS5 | |
| SCHEMBL941841 | 0.74 | MMP13 (0.72) | MMP13MMP12MMP14ADAMTS5 | |
| SCHEMBL8233841 | 0.74 | MMP13 (0.72) | MMP13MMP12MMP14ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | MMP13 19/4885MMP12 1/4885MMP14 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.